RXi Pharmaceuticals Corp (RXII) Analysts See $-0.20 EPS

August 1, 2017 - By Adrian Erickson

 RXi Pharmaceuticals Corp (RXII) Analysts See $ 0.20 EPS

Analysts expect RXi Pharmaceuticals Corp (NASDAQ:RXII) to report $-0.20 EPS on August, 10.They anticipate $0.14 EPS change or 41.18 % from last quarter’s $-0.34 EPS. After having $-0.12 EPS previously, RXi Pharmaceuticals Corp’s analysts see 66.67 % EPS growth. The stock decreased 4.85% or $0.031 during the last trading session, reaching $0.61. About 103,183 shares traded. RXi Pharmaceuticals Corp (NASDAQ:RXII) has declined 75.22% since August 1, 2016 and is downtrending. It has underperformed by 91.92% the S&P500.

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid interference (RNAi) firm developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The company has market cap of $13.50 million. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator. It currently has negative earnings. The Company’s clinical development programs include RXI-109, an sd-rxRNA, for the treatment of dermal and ocular scarring, and Samcyprone for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma.

More notable recent RXi Pharmaceuticals Corp (NASDAQ:RXII) news were published by: Prnewswire.com which released: “RXi Pharmaceuticals Announces Reverse Stock Split” on April 15, 2016, also Prnewswire.com with their article: “RXi Pharmaceuticals to Present at Leading Investor and Healthcare Conferences” published on February 08, 2017, Prnewswire.com published: “RXi Pharmaceuticals Enters into Exclusive Option Agreement to Acquire …” on October 12, 2016. More interesting news about RXi Pharmaceuticals Corp (NASDAQ:RXII) were released by: Prnewswire.com and their article: “RXi Pharmaceuticals Announces Completion of Enrollment of Phase 1/2 Clinical …” published on June 21, 2017 as well as Prnewswire.com‘s news article titled: “RXi Pharmaceuticals Corporation Selected to Present at the Cavendish Global …” with publication date: May 01, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.